CarBio Therapeutics

CarBio Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of chimeric antigen receptor (CAR) T-cell therapies for cancer. The company was co-founded by experts from the University of Pennsylvania to translate cutting-edge research into effective treatments for both liquid and solid tumors. CarBio's lead programs target well-validated antigens like CD19 for hematological cancers and Mesothelin for challenging solid tumors such as pancreatic and ovarian cancer. By utilizing proprietary genetic engineering techniques, the company aims to enhance the durability and potency of T-cell responses within the immunosuppressive tumor microenvironment. CarBio maintains a strong presence in both China and the United States to facilitate global clinical development and manufacturing.